SLC7A5 and neoplasm: A recent investigation has documented that the inhibition of the glutamine transporter, specifically the carrier family 7 member 5 (SLC7A5), in conjunction with anti-PD-L1 treatment, significantly augments the immune response within the tumor microenvironment [64].